NCT05703880View on ClinicalTrials.gov

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

CompletedOBSERVATIONAL
Enrollment

15,948

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Chronic Kidney DiseaseType 2 Diabetes Mellitus
Interventions
DRUG

Finerenone (Kerendia, BAY948862)

Retrospective cohort analysis using United States Optum EHR data and OM1 RWDC databases.

Trial Locations (2)

55344

Optum electronic health records (EHR) database, Eden Prairie

02116

OM1 Real-World Data Cloud (RWDC), Boston

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05703880 - An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | Biotech Hunter | Biotech Hunter